Changzhou KangXin Medical Instruments Co., Ltd.

Recently, Changzhou Kangxin Medical Instruments Co., Ltd. reached a significant milestone in its globalization strategy. From September 29th to October 2nd, a team of audit experts from the Kazakhstan Drug Administration visited the company for a four-day on-site pre-market review of its medical device products. The successful completion of this review lays a solid foundation for Kangxin Medical's core products, including antegrade cannulas, arterial cannulas, venous cannulas, and femoral cannulas, to enter the Kazakhstan and broader Central Asian markets.

Strict Audit Demonstrates International Quality

During the audit, Kazakh experts conducted a comprehensive, detailed, and in-depth assessment of Changzhou Kangxin Medical's quality management system, product R&D and design control, the entire manufacturing process, sterilization validation, testing capabilities, and supplier management, in accordance with their country's strict medical device regulations. The audit experts visited the company's high-cleanliness production workshops and advanced laboratories and conducted a rigorous review of relevant technical documents.

Changzhou Kangxin Medical fully cooperated with the audit with professionalism, openness, and transparency. The company's comprehensive quality management system, highly automated production processes, and unwavering commitment to product quality earned high recognition from the auditors.

Deepening Core Strengths to Expand into the Eurasian Market

As a key country along the Belt and Road Initiative, Kazakhstan boasts enormous potential in the medical market. This audit is not only a necessary step for product approval but also serves as a bridge for Changzhou Kangxin Medical to establish in-depth cooperation with the Central Asian region.

About Changzhou Kangxin Medical Instrument Co., Ltd.

Established in 2006, Changzhou Kangxin Medical Instrument Co., Ltd. is a national high-tech enterprise specializing in the research, development, and production of disposable sterile medical devices. The company holds 67 patents and 63 certifications, and its products cover extracorporeal circulation, cardiac intervention, and minimally invasive surgery, serving customers in over 30 countries and regions worldwide.

Passing the Kazakhstan Food and Drug Administration's audit not only opens the door to the Central Asian market for Kangxin Medical, but also demonstrates the strength of Chinese medical device companies in aligning with international standards. As the Belt and Road Initiative deepens, Kangxin Medical will continue to be driven by innovation to provide safer and more efficient medical solutions to patients worldwide.